<DOC>
	<DOCNO>NCT01978483</DOCNO>
	<brief_summary>Ultraviolet ( UV ) light part normal sunlight many effect human skin health . One harmful effect long-term UV light exposure cause skin cancer . The mechanism UV light cause skin cancer entirely understood . One way UV light cause cancer modify DNA molecule cell skin . Another mechanism involve cancer formation UV light immunosuppression . By mechanism , UV light inactivates cell immune system skin . The immune cell responsible detection destruction foreign substance organisms bacteria virus also recognize destroy cancer cell . UV light know prevent cell immune system destroy cancer cell . In laboratory experiment , medication call denosumab show diminish inhibition ultraviolet-induced suppression skin immunity . In word , medication could block effect UV cell immune system might allow patient take drug well protect skin cancer . The objective study test whether denosumab block immunosuppressive effect UVB light healthy subject . This study divide two stage . In first stage , ten subject ( Cohort 1 ) sensitize diphenylcyclopropenone ( DPCP ) , topical sensitizer commonly use treatment alopecia areata cutaneous wart . By reexposing subject DPCP incremental dos , dose-response level cutaneous hypersensitivity reaction normal skin obtain . This allow comparison normal level DPCP-induced cutaneous hypersensitivity ( CHS ) reaction non UV-exposed skin ( Cohort 1 ) CHS obtain two UVB-exposed experimental group Cohort 2 . In second stage study , 20 subject ( Cohort 2 ) expose immunosuppressive dose ultraviolet B ( UVB ) 24 hour prior DPCP sensitization . This expected result abolition CHS upon rechallenge DPCP . In order ass whether denosumab reverse UVB-induced immunosuppression , subject previously randomize receive single 1mL injection either 60 mg denosumab ( group A ; 10 subject ) 1 mL saline ( group B ; 10 subject ) two week UVB exposure . CHS reaction elicit DPCP rechallenge compare denosumab saline group .</brief_summary>
	<brief_title>Effect RANKL Inhibition UV-induced Immunosuppression</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Delayed</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>1 . Men postmenopausal woman 18 year age old time consent . 2 . Male subject female partner ( criterion apply postmenopausal female ) willing use effective contraceptive method least 30 day Day 0 least 1 month last study drug administration . Effective contraceptive method : 1 . Barrier method condom , sponge diaphragm combine spermicide foam , gel cream ; 2 . Hormonal contraception ( oral , intramuscular , implant transdermal ) include DepoProvera , Evra Nuvaring ; 3 . Intrauterine device ( IUD ) ; 4 . Sterilization tubal ligation , hysterectomy vasectomy ; 5 . Postmenopausal state least 1 year female subject female partner male subject ; 6 . Samesex partner ; 7 . Abstinence . 3 . Capable give informed consent consent must obtain prior study related procedure . 4 . Fitzpatrick skin phototypes II III . 5 . Subject weigh 100kg le . 1 . Conditions medication cause immunosuppression , photosensitization phototoxicity . 2 . Past history skin cancer subject precancerous skin lesion ( eg . actinic keratosis ) . 3 . Subject atopic dermatitis ( cohort 1 ) 4 . Subject receive investigational drug within 28 day 5 halflives , whichever longer , prior Day 0 plan study period . 5 . Subject use topical medication arm buttock within 14 day Day 0 plan study . 6 . At investigator 's discretion subject current past history alcohol drug abuse would interfere ability subject comply study protocol . 7 . Hypersensitivity/allergy denosumab . 8 . Hypersensitivity/allergy lidocaine . 9 . Hypersensitivity/allergy latex . 10 . Subject take anticoagulant medication except low dose acetylsalicylic acid . 11 . Past history hypocalcemia predispose factor ( eg , history hypoparathyroidism , thyroid surgery , parathyroid surgery , malabsorption syndrome , excision small intestine , severe renal impairment receive dialysis ) . 12 . Known vitamin D deficiency . 13 . Creatinine clearance less 30mL/min ( Cohort 2 ) . 14 . Corrected calcium concentration inferior normal range ( Cohort 2 ) . 15 . Past history osteonecrosis jaw ( ONJ ) risk factor ONJ ( poor oral hygiene , periodontal and/or preexist dental disease , diagnosis cancer bone lesion , invasive dental procedure dental extraction implant within 6 month screen visit . ) 16 . Past history keloid hypertrophic scar . 17 . Prior treatment diphenylcyclopropenone . 18 . Treatment denosumab past 12 month . 19 . Significant limitation range motion arm shoulder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Humans</keyword>
	<keyword>Adult</keyword>
	<keyword>skin</keyword>
	<keyword>metabolism</keyword>
	<keyword>radiation effect</keyword>
	<keyword>Ultraviolet Rays</keyword>
	<keyword>RANKL</keyword>
	<keyword>RANK Ligand</keyword>
	<keyword>denosumab</keyword>
	<keyword>diphenylcyclopropenone</keyword>
	<keyword>diphencyprone</keyword>
	<keyword>immunology</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Dermatitis , Allergic Contact</keyword>
	<keyword>Hypersensitivity , Delayed</keyword>
</DOC>